Further evidence of possible therapeutic uses of Sambucus nigra L. extracts by the assessment of the In Vitro and In Vivo anti-inflammatory properties of Its PLGA and PCL-Based Nanoformulations

Bibliographic Details
Main Author: Mota, Ana Henriques
Publication Date: 2020
Other Authors: Duarte, Noélia, Serra, Ana Teresa, Ferreira, António, Bronze, Maria Rosário, Custódio, Luísa, Gaspar, Maria Manuela, Simões, Sandra, Rijo, Patrícia, Ascensão, Lia, Faísca, Pedro, Viana, Ana Silveira, Pinto, Rui, Kumar, Pradeep, Almeida, António José, Reis, Catarina Pinto
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10400.1/14961
Summary: <i>Sambucus nigra</i> L. is widely used in traditional medicine with different applications. However, confirmative studies are strongly required. This study aimed to assess the biological activities of the <i>S. nigra</i> flower’s extract encapsulated into two different types of nanoparticles for optimizing its properties and producing further evidence of its potential therapeutic uses. Different nanoparticles (poly(lactide-co-glycolide, PLGA) and poly-Ɛ-caprolactone (PCL), both with oleic acid, were prepared by emulsification/solvent diffusion and solvent-displacement methods, respectively. Oleic acid was used as a capping agent. After the nanoparticles’ preparation, they were characterized and the biological activities were studied in terms of collagenase, in vitro and in vivo anti-inflammatory, and in vitro cell viability. Rutin and naringenin were found to be the major phenolic compounds in the studied extract. The encapsulation efficiency was higher than 76% and revealed to have an impact on the release of the extract, mainly for the PLGA. Moreover, biochemical and histopathological analyses confirmed that the extract-loaded PLGA-based nanoparticles displayed the highest anti-inflammatory activity. In addition to supporting the previously reported evidence of potential therapeutic uses of <i>S. nigra</i>, these results could draw the pharmaceutical industry’s interest to the novelty of the nanoproducts.
id RCAP_60cf0a3d96e90da7686c2207f0ad87fc
oai_identifier_str oai:sapientia.ualg.pt:10400.1/14961
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Further evidence of possible therapeutic uses of Sambucus nigra L. extracts by the assessment of the In Vitro and In Vivo anti-inflammatory properties of Its PLGA and PCL-Based NanoformulationsSambucus nigra LNanoparticlesAnti-inflammatory activityCollagenase inhibitionSafety assessment<i>Sambucus nigra</i> L. is widely used in traditional medicine with different applications. However, confirmative studies are strongly required. This study aimed to assess the biological activities of the <i>S. nigra</i> flower’s extract encapsulated into two different types of nanoparticles for optimizing its properties and producing further evidence of its potential therapeutic uses. Different nanoparticles (poly(lactide-co-glycolide, PLGA) and poly-Ɛ-caprolactone (PCL), both with oleic acid, were prepared by emulsification/solvent diffusion and solvent-displacement methods, respectively. Oleic acid was used as a capping agent. After the nanoparticles’ preparation, they were characterized and the biological activities were studied in terms of collagenase, in vitro and in vivo anti-inflammatory, and in vitro cell viability. Rutin and naringenin were found to be the major phenolic compounds in the studied extract. The encapsulation efficiency was higher than 76% and revealed to have an impact on the release of the extract, mainly for the PLGA. Moreover, biochemical and histopathological analyses confirmed that the extract-loaded PLGA-based nanoparticles displayed the highest anti-inflammatory activity. In addition to supporting the previously reported evidence of potential therapeutic uses of <i>S. nigra</i>, these results could draw the pharmaceutical industry’s interest to the novelty of the nanoproducts.MDPISapientiaMota, Ana HenriquesDuarte, NoéliaSerra, Ana TeresaFerreira, AntónioBronze, Maria RosárioCustódio, LuísaGaspar, Maria ManuelaSimões, SandraRijo, PatríciaAscensão, LiaFaísca, PedroViana, Ana SilveiraPinto, RuiKumar, PradeepAlmeida, António JoséReis, Catarina Pinto2021-01-14T12:02:06Z2020-12-042021-01-08T14:44:30Z2020-12-04T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/14961engdoi: 10.3390/pharmaceutics121211811999-492310.3390/pharmaceutics12121181info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-02-18T17:46:36Zoai:sapientia.ualg.pt:10400.1/14961Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T20:35:30.216065Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Further evidence of possible therapeutic uses of Sambucus nigra L. extracts by the assessment of the In Vitro and In Vivo anti-inflammatory properties of Its PLGA and PCL-Based Nanoformulations
title Further evidence of possible therapeutic uses of Sambucus nigra L. extracts by the assessment of the In Vitro and In Vivo anti-inflammatory properties of Its PLGA and PCL-Based Nanoformulations
spellingShingle Further evidence of possible therapeutic uses of Sambucus nigra L. extracts by the assessment of the In Vitro and In Vivo anti-inflammatory properties of Its PLGA and PCL-Based Nanoformulations
Mota, Ana Henriques
Sambucus nigra L
Nanoparticles
Anti-inflammatory activity
Collagenase inhibition
Safety assessment
title_short Further evidence of possible therapeutic uses of Sambucus nigra L. extracts by the assessment of the In Vitro and In Vivo anti-inflammatory properties of Its PLGA and PCL-Based Nanoformulations
title_full Further evidence of possible therapeutic uses of Sambucus nigra L. extracts by the assessment of the In Vitro and In Vivo anti-inflammatory properties of Its PLGA and PCL-Based Nanoformulations
title_fullStr Further evidence of possible therapeutic uses of Sambucus nigra L. extracts by the assessment of the In Vitro and In Vivo anti-inflammatory properties of Its PLGA and PCL-Based Nanoformulations
title_full_unstemmed Further evidence of possible therapeutic uses of Sambucus nigra L. extracts by the assessment of the In Vitro and In Vivo anti-inflammatory properties of Its PLGA and PCL-Based Nanoformulations
title_sort Further evidence of possible therapeutic uses of Sambucus nigra L. extracts by the assessment of the In Vitro and In Vivo anti-inflammatory properties of Its PLGA and PCL-Based Nanoformulations
author Mota, Ana Henriques
author_facet Mota, Ana Henriques
Duarte, Noélia
Serra, Ana Teresa
Ferreira, António
Bronze, Maria Rosário
Custódio, Luísa
Gaspar, Maria Manuela
Simões, Sandra
Rijo, Patrícia
Ascensão, Lia
Faísca, Pedro
Viana, Ana Silveira
Pinto, Rui
Kumar, Pradeep
Almeida, António José
Reis, Catarina Pinto
author_role author
author2 Duarte, Noélia
Serra, Ana Teresa
Ferreira, António
Bronze, Maria Rosário
Custódio, Luísa
Gaspar, Maria Manuela
Simões, Sandra
Rijo, Patrícia
Ascensão, Lia
Faísca, Pedro
Viana, Ana Silveira
Pinto, Rui
Kumar, Pradeep
Almeida, António José
Reis, Catarina Pinto
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Sapientia
dc.contributor.author.fl_str_mv Mota, Ana Henriques
Duarte, Noélia
Serra, Ana Teresa
Ferreira, António
Bronze, Maria Rosário
Custódio, Luísa
Gaspar, Maria Manuela
Simões, Sandra
Rijo, Patrícia
Ascensão, Lia
Faísca, Pedro
Viana, Ana Silveira
Pinto, Rui
Kumar, Pradeep
Almeida, António José
Reis, Catarina Pinto
dc.subject.por.fl_str_mv Sambucus nigra L
Nanoparticles
Anti-inflammatory activity
Collagenase inhibition
Safety assessment
topic Sambucus nigra L
Nanoparticles
Anti-inflammatory activity
Collagenase inhibition
Safety assessment
description <i>Sambucus nigra</i> L. is widely used in traditional medicine with different applications. However, confirmative studies are strongly required. This study aimed to assess the biological activities of the <i>S. nigra</i> flower’s extract encapsulated into two different types of nanoparticles for optimizing its properties and producing further evidence of its potential therapeutic uses. Different nanoparticles (poly(lactide-co-glycolide, PLGA) and poly-Ɛ-caprolactone (PCL), both with oleic acid, were prepared by emulsification/solvent diffusion and solvent-displacement methods, respectively. Oleic acid was used as a capping agent. After the nanoparticles’ preparation, they were characterized and the biological activities were studied in terms of collagenase, in vitro and in vivo anti-inflammatory, and in vitro cell viability. Rutin and naringenin were found to be the major phenolic compounds in the studied extract. The encapsulation efficiency was higher than 76% and revealed to have an impact on the release of the extract, mainly for the PLGA. Moreover, biochemical and histopathological analyses confirmed that the extract-loaded PLGA-based nanoparticles displayed the highest anti-inflammatory activity. In addition to supporting the previously reported evidence of potential therapeutic uses of <i>S. nigra</i>, these results could draw the pharmaceutical industry’s interest to the novelty of the nanoproducts.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-04
2020-12-04T00:00:00Z
2021-01-14T12:02:06Z
2021-01-08T14:44:30Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.1/14961
url http://hdl.handle.net/10400.1/14961
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv doi: 10.3390/pharmaceutics12121181
1999-4923
10.3390/pharmaceutics12121181
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833598733729660928